Immunotherapy

• The FDA has approved a new engineered viral immunotherapy designed specifically for patients suffering from treatment-resistant advanced melanoma. • This approval provides a critical new therapeutic option for cancer patients who have failed to respond to existing standard-of-care treatments. • The authorization is granted under conditions where continued market availability may be contingent upon the verification of clinical benefits.

• Researchers at UCL and UCLH conducted a trial where patients with stage 2 or 3 colorectal cancer received just nine weeks of pembrolizumab immunotherapy before surgery, challenging the standard approach of surgery followed by months of chemotherapy. • Early results showed 59% of patients had no detectable cancer after completing immunotherapy and undergoing surgery, and after 33 months of follow-up, none of the patients have experienced a relapse. • This outcome represents a significant shift in colorectal cancer treatment protocols, suggesting that short bursts of targeted immunotherapy prior to surgery may deliver more durable results than conventional post-operative chemotherapy regimens.

Injectable pembrolizumab can treat several types of cancer and can be administered in under two minutesThousands of patients across England each year will benefit from a new immunotherapy treatment that can be used for several types of cancer, the NHS has announced.The injectable form of pembrolizumab, which can be administered in under two minutes, kills cancer cells by blocking a protein called PD-1, which acts as a brake on immune responses, allowing the immune system to recognise and attack cancer cells. Continue reading...